ARGX
argenx SE
454.23
USD
This page is just a preview of the data found in TrendSpider’s full version
argenx SE stock is down -9.15% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 30 Nov 15:32 | 21 Jun, 2024 | 500.00 | 0 | ||
| 30 Nov 15:35 | 17 May, 2024 | 500.00 | 1 | ||
| 30 Nov 15:36 | 17 May, 2024 | 490.00 | 0 | ||
| 30 Nov 15:36 | 17 May, 2024 | 490.00 | 0 | ||
| 30 Nov 19:41 | 15 Dec, 2023 | 470.00 | 33 | ||
| 01 Dec 14:32 | 16 Feb, 2024 | 460.00 | 0 | ||
| 01 Dec 15:20 | 19 Jan, 2024 | 460.00 | 8 | ||
| 01 Dec 15:21 | 16 Feb, 2024 | 470.00 | 5 | ||
| 01 Dec 15:29 | 16 Feb, 2024 | 450.00 | 30 | ||
| 01 Dec 16:28 | 19 Jan, 2024 | 470.00 | 9 |
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.
